MA28985B1 - Analogues de loxapine et methodes d'utilisation - Google Patents

Analogues de loxapine et methodes d'utilisation

Info

Publication number
MA28985B1
MA28985B1 MA29765A MA29765A MA28985B1 MA 28985 B1 MA28985 B1 MA 28985B1 MA 29765 A MA29765 A MA 29765A MA 29765 A MA29765 A MA 29765A MA 28985 B1 MA28985 B1 MA 28985B1
Authority
MA
Morocco
Prior art keywords
methods
loxapine
analogues
relates
novel compounds
Prior art date
Application number
MA29765A
Other languages
English (en)
Inventor
Dale M Edgar
David G Hangauer
Kazumi Shiosaki
Michael Solomon
James F White
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Publication of MA28985B1 publication Critical patent/MA28985B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés et des méthodes d'utilisation de ceux-ci pour moduler le sommeil.
MA29765A 2004-09-21 2007-03-20 Analogues de loxapine et methodes d'utilisation MA28985B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19

Publications (1)

Publication Number Publication Date
MA28985B1 true MA28985B1 (fr) 2007-11-01

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29765A MA28985B1 (fr) 2004-09-21 2007-03-20 Analogues de loxapine et methodes d'utilisation

Country Status (19)

Country Link
US (3) US7592333B2 (fr)
EP (1) EP1804804B1 (fr)
JP (1) JP5049129B2 (fr)
KR (1) KR101264444B1 (fr)
AT (1) ATE542536T1 (fr)
AU (1) AU2005286713B2 (fr)
BR (1) BRPI0515518A (fr)
CA (1) CA2580250C (fr)
CY (1) CY1112590T1 (fr)
DK (1) DK1804804T3 (fr)
EA (1) EA012610B1 (fr)
ES (1) ES2378452T3 (fr)
MA (1) MA28985B1 (fr)
MX (1) MX2007003032A (fr)
NO (1) NO20071604L (fr)
NZ (1) NZ553900A (fr)
PL (1) PL1804804T3 (fr)
PT (1) PT1804804E (fr)
WO (1) WO2006034414A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
EP1994932A1 (fr) * 2003-01-23 2008-11-26 Arcadia Pharmaceuticals Inc. Utilisation de N-desmethylclozapine pour traiter les psychoses humaines
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US7550454B2 (en) * 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2006001866A2 (fr) * 2004-04-01 2006-01-05 Acadia Pharmaceuticals Inc. Synthese et isolation de n-demethylclozapine et formes cristallines correspondantes
US7563785B2 (en) * 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
KR101312993B1 (ko) * 2006-10-28 2013-11-25 엔비보 파마슈티칼즈, 인코퍼레이티드 히스톤 데아세틸라아제의 억제제
AU2008225014B2 (en) * 2007-03-15 2014-12-11 Protocell Therapeutics, Inc. Dibenzo(b,f)(1,4)oxazapine compounds
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
CN104069567A (zh) 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
CN102245137A (zh) 2008-11-07 2011-11-16 茵苏莱恩医药有限公司 用于药物递送的装置和方法
WO2014116684A1 (fr) * 2013-01-22 2014-07-31 Edward Roberts Modulateurs de récepteur de neuropeptide y non peptidique
CA2980162C (fr) 2015-03-26 2024-06-18 Jacqueline M. Iversen Procedes et compositions pour inhiber les symptomes associes a la veisalgie
WO2021080997A1 (fr) 2019-10-21 2021-04-29 Alairion, Inc. Dérivés de l'acide 3-(4-(11h-dibenzo[b,e][1,4]azépin-6-yl)pipérazin-1-yl)- et 3-(4-(dibenzo[b,f][1,4]oxazépin/thiazépin/diazépin-11-yl)pipérazin-1-yl)-propanoïque utilisés comme modulateurs des récepteurs h1 et 5-ht2a pour le traitement des troubles du sommeil

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (fr) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
DE69429119T2 (de) 1993-07-09 2002-07-18 R.P. Scherer Corp., Troy Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
WO1998036738A1 (fr) 1997-02-20 1998-08-27 Therics, Inc. Forme galenique presentant des proprietes de dispersion rapide, ses procedes d'utilisation et son procede de preparation
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
WO2003039255A1 (fr) 2001-11-05 2003-05-15 Basf Aktiengesellschaft Derives de dibenzothiepine substitues utilises comme agents insecticides, acaricides et nematicides
EP1578198A1 (fr) * 2002-12-20 2005-09-28 Basf Aktiengesellschaft Derivés de dibenzo(hetero)azepine pesticides
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
PL1804804T3 (pl) 2012-08-31
US20090186872A1 (en) 2009-07-23
KR101264444B1 (ko) 2013-05-20
EA200700702A1 (ru) 2007-10-26
CY1112590T1 (el) 2016-02-10
US20060063755A1 (en) 2006-03-23
CA2580250A1 (fr) 2006-03-30
WO2006034414A3 (fr) 2006-09-08
BRPI0515518A (pt) 2008-07-29
AU2005286713A1 (en) 2006-03-30
EP1804804A4 (fr) 2010-11-24
EP1804804A2 (fr) 2007-07-11
KR20070060126A (ko) 2007-06-12
CA2580250C (fr) 2013-05-14
US8101596B2 (en) 2012-01-24
AU2005286713B2 (en) 2010-10-28
NO20071604L (no) 2007-06-20
US20060063928A1 (en) 2006-03-23
MX2007003032A (es) 2007-05-21
EP1804804B1 (fr) 2012-01-25
JP2008513510A (ja) 2008-05-01
US7592333B2 (en) 2009-09-22
JP5049129B2 (ja) 2012-10-17
ATE542536T1 (de) 2012-02-15
WO2006034414A2 (fr) 2006-03-30
DK1804804T3 (da) 2012-02-20
PT1804804E (pt) 2012-03-30
EA012610B1 (ru) 2009-10-30
NZ553900A (en) 2010-10-29
ES2378452T3 (es) 2012-04-12

Similar Documents

Publication Publication Date Title
MA28985B1 (fr) Analogues de loxapine et methodes d'utilisation
WO2006049734A3 (fr) Analogues de quetiapine et leurs procedes d'utilisation
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE416168T1 (de) Modulatoren des vanilloidrezeptors
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
DE60327306D1 (de) Modifizierter russ
UA94221C2 (en) Lipocalin protein
BR0317715A (pt) Composições e processos de uso de collajolie
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
SE0301653D0 (sv) Novel compounds
NO20043564L (no) Follistatindomene som inneholder proteiner
BRPI0411528A (pt) uso de isomalte como prebiótico
DK1549638T3 (da) Indol-3-carboxamider som glucokinase (GK) aktivatorer
DE60335716D1 (de) Beschleuniger-zusammensetzung
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
DE60324641D1 (de) Schäumbare Emulsion des Öl-in-Waser-Typs
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
MX2007003398A (es) Sulfonamidas y sus usos.
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
UY28344A1 (es) Nuevos compuestos
DE50309381D1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
IL178149A0 (en) Novel phenantridine analogues and their uses as inhibitors of hyperproliferation of t cells and/or keratinocytes
NO20024880D0 (no) Sammensetning inneholdende fosfat
WO2006010077A3 (fr) Promedicaments de lonidamine et analogues de lonidamine